3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Gliosarcoma
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
Temozolomide
48
Bevacizumab
29
Carmustine
17
Erlotinib Hydrochloride
16
Radiotherapy
14
Irinotecan
14
Surgical Procedures, Operative
10
Sirolimus
10
Imatinib Mesylate
10
Carboplatin
10
Sorafenib
9
O(6)-benzylguanine
9
Filgrastim
9
Etoposide
8
temsirolimus
7
sargramostim
7
Radiosurgery
7
Radiation
7
Procarbazine
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
aldesleukin
6
Topotecan
6
Thalidomide
6
Vorinostat
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Hydroxyurea
5
Gefitinib
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
depatuxizumab mafodotin
×
Sarcoma
×
Clear all
NCT02573324
2023-05-11
Intellance1
AbbVie
Phase 3
Completed
691 enrolled
28 charts